Explore Business Standard
Kidney Diseases
India had the second-highest number of people with chronic kidney disease in 2023 at 138 million, following China at 152 million, according to a global study published in The Lancet journal. The condition was the ninth-leading cause of death and claimed nearly 15 lakh lives globally the same year, researchers led by those at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington and other institutes in the US and UK found. The highest prevalence was seen in North Africa and the Middle East at 18 per cent each, nearly 16 per cent in South Asia and over 15 per cent in each of Sub-Saharan Africa and Latin America and the Caribbean. Chronic kidney disease is a major contributor to heart disease and accounted for almost 12 per cent of cardiovascular deaths around the world in 2023. It ranked as the seventh leading cause for heart-related mortality, ahead of diabetes and obesity, the team said. Fourteen risk factors for chronic kidney disease were detailed
An analysis of deaths in the wake of tropical cyclones in nine countries has found that the highest increase of 92 per cent was seen in deaths due to kidney diseases, followed by 21 per cent in deaths due to physical injuries. A tropical cyclone is an extreme weather event originating in oceans in the tropics, bringing violent winds, torrential rains and in some cases, destructive coastal flooding. Deaths due to diabetes were seen to increase by 15 per cent, and those due to neuropsychiatric disorders and infectious diseases by 12 per cent and 11 per cent, respectively, according to findings published in The British Medical Journal. Researchers led by those at Monash University looked at 14.8 million deaths linked to 217 tropical cyclones during 2000-2019 across 1,356 communities in nine countries including Australia, Brazil, the Philippines and Thailand. "Mortality risks from various causes consistently increased after tropical cyclones, with peaks occurring within the first two .
Chronic kidney disease (CKD) is emerging as one of the country's most pressing public health concerns, a renowned nephrologist said. CKD is fuelled by lifestyle disorders like diabetes and hypertension and compounded by environmental and occupational factors, kidney ailments are no longer confined to the elderly or the urban elite, he said. If left unchecked, kidney disease could soon take on the proportions of an epidemic, the nephrologist said. Talking to PTI, Dr H Sudarshan Ballal shared his experience of witnessing how India's renal healthcare evolved from scarcity to scale but also watched new challenges emerge with unsettling speed. "When I returned to India in 1991 from the US, there were just 800 nephrologists in the entire country. In fact, there were more Indian nephrologists practising in the US than in India. We used to call ourselves one in a million," Ballal recalled. Three decades later, the situation has undoubtedly improved, with thousands of specialists and advan
The Madhya Pradesh government has banned the sale of Coldrif cough syrup following the death of 14 children in Chhindwara due to suspected renal failure, with officials stating the drug samples were found to contain a highly toxic substance. The Central Drugs Standard Control Organisation (CDSCO) has also initiated risk-based inspections at the manufacturing units of 19 drugs, including cough syrups and antibiotics, across six states, the Union health ministry said on Saturday. A sample of the syrup, tested by the government drug analyst at the Drug Testing Laboratory in Chennai, was declared "Not of Standard Quality" by the Tamil Nadu Directorate of Drug Control, officials said here. The action by the Madhya Pradesh government came in the wake of the deaths of 14 children in Chhindwara district due to suspected kidney failure. Of these, 10 deaths were reported in Parasia subdivision since September 7, local officials said. Yogita (2), a resident of Parasia, died at a Nagpur hospit
Pharma major Lupin Ltd on Thursday said it has received approval from the US health regulator for its generic version of Tolvaptan tablets indicated for a certain type of kidney disease. The approval by the US Food and Drug Administration (USFDA) is for the abbreviated new drug application for Tolvaptan tablets of strengths 15 mg, 30 mg, 45 mg, 60 mg, and 90 mg, Lupin said in a regulatory filing. These are bioequivalent to Jynarque tablets in the same strengths of Otsuka Pharmaceutical Company Ltd, it added. "Lupin is the exclusive first-to-file for this product and is eligible for 180 days of generic drug exclusivity. This product will be manufactured at Lupin's Nagpur facility and will be launched soon," the company said. Commenting on the approval, Lupin CEO Vinita Gupta said,"This marks a significant entry into the nephrology segment and demonstrates our commitment to addressing the unmet needs of patients globally." Tolvaptan is indicated to slow kidney function decline in .
President Droupadi Murmu on Monday condoled the demise of veteran filmmaker Shyam Benegal and said his passing away marks the end of a glorious chapter of Indian cinema and television. Murmu said Benegal started a new kind of cinema and crafted several classics. "A veritable institution, he groomed many actors and artists. His extraordinary contribution was recognised in the form of numerous awards including Dadasaheb Phalke Award and Padma Bhushan. My condolences to the members of his family and his countless admirers," the President said in a post on X. Benegal, who heralded a new era in Hindi cinema with the 'parallel movement' in the 1970s and 1980s with classics such as "Ankur", "Mandi" and "Manthan", died on Monday at a hospital in Mumbai after battling chronic kidney disease. He was 90. "The passing of Shri Shyam Benegal marks the end of a glorious chapter of Indian cinema and television," Murmu said.
Complying with the WHO-recommended levels of sodium intake could avert three lakh deaths due to heart and chronic kidney disease in 10 years, a modelling study by the World Health Organization has estimated. High levels of sodium -- an ingredient of salt -- are one of the main dietary risks of death and disability. Packaged foods are a major source of sodium intake in high-income countries, and increasingly becoming so in low- and middle-income countries. However, researchers, including those from The George Institute for Global Health, Hyderabad, said that India has no national strategy for sodium reduction despite people consuming double the recommended intake and increasing amounts of packaged foods. The WHO recommends under two grams of sodium a day, which is roughly the same as less than a teaspoon or five grams of salt a day. Published in The Lancet Public Health journal, the results suggested substantial health gains and cost savings within the first ten years of compliance,